Reviva Pharmaceuticals Holdings (RVPH) Research & Development (2021 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Research & Development of $1.4 million for Q1 2026, down 17.48% sequentially from $1.7 million in Q4 2025, and down 65.11% YoY from $4.1 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Research & Development (2021 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Research & Development for 6 years, with the latest figure at $1.4 million in Q1 2026.
- Quarterly Research & Development fell 65.11% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 57.48% YoY) and the FY2025 annual result came in at $11.7 million, down 48.89% from the prior year.
- Research & Development declined to $1.4 million in Q1 2026 per RVPH's latest filing, from $1.7 million in the prior quarter.
- Over five years, Research & Development peaked at $9.6 million in Q3 2023 and troughed at $1.4 million in Q1 2026.
- A 5-year average of $5.3 million and a median of $5.5 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 1390.44% in 2022, then sank 68.92% in 2025.
- Over 5 years, Research & Development stood at $7.4 million in 2022, then grew by 9.32% to $8.1 million in 2023, then plunged by 42.26% to $4.7 million in 2024, then slumped by 62.85% to $1.7 million in 2025, then dropped by 17.48% to $1.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.4 million, $1.7 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 97.90 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.34 Mn | 6.34 Mn | - | 1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.44 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 3.72 Mn |
| Mar 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | 4.68 Mn |
| Sep 30, 2024 | 6.86 Mn |
| Jun 30, 2024 | 5.58 Mn |
| Mar 31, 2024 | 5.78 Mn |
| Dec 31, 2023 | 8.11 Mn |
| Sep 30, 2023 | 9.57 Mn |
| Jun 30, 2023 | 8.26 Mn |
| Mar 31, 2023 | 5.48 Mn |
| Dec 31, 2022 | 7.42 Mn |
| Sep 30, 2022 | 4.24 Mn |
| Jun 30, 2022 | 4.51 Mn |
| Mar 31, 2022 | 5.83 Mn |
| Dec 13, 2021 | 2.66 Mn |
| Sep 30, 2021 | 1.42 Mn |